Evidence map›Paper›PMID 41472274›Full record

ArticleViruses2025

High-Fidelity and Cost-Effective Engineering of SARS-CoV-2.

Marco Olguin-Nava, Thomas Hennig, Charlene Börtlein, Patrick Bohn, Uddhav B Ambi, Alexander Gabel, Lina M Günter, Anne-Sophie Gribling-Burrer, Nora Schmidt, Neva Caliskan and 3 more

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marco Olguin-NavaHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.
Thomas HennigInstitute of Virology, Hannover Medical School, 30625 Hannover, Germany.
Charlene BörtleinHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.
Patrick BohnHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.ORCID 0000-0002-8515-2067
Uddhav B AmbiHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.ORCID 0000-0001-7266-1324
Alexander GabelHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.ORCID 0000-0002-8064-3289
Lina M GünterHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.ORCID 0009-0009-1344-8844
Anne-Sophie Gribling-BurrerHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.
Nora SchmidtHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.ORCID 0000-0002-3232-3491
Neva CaliskanHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.
Lars DölkenInstitute of Virology, Hannover Medical School, 30625 Hannover, Germany.
Mathias MunschauerHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.
Redmond P SmythHelmholtz Institute for RNA-Based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.ORCID 0000-0002-1580-0671

Funding

Agence Nationale de la Recherche ANR-10-IDEX-0002Agence Nationale de la Recherche ANR-17-EURE-0023Agence Nationale de la Recherche ANR 20-SFRI-0012Helmholtz Association of German Research Centres VH-NG-1347
6 · The paper itself

Abstract

Efficient reverse genetics systems are essential for understanding SARS-CoV-2 pathogenesis, host-virus interactions, and potential therapeutic interventions. Here, we developed a cost-effective PCR-based reverse genetics platform that splits the SARS-CoV-2 genome into only six bacterial plasmids, enabling cloning, manipulation, and the rescue of recombinant SARS-CoV-2 (rSARS-CoV-2) with high fidelity and high viral titers after a single passage. Using this system, we generated and characterized spike protein mutants Y453F and N501Y, as well as a U76G mutation in the 5'-UTR. Y453F showed reduced replication kinetics, lower cell binding, and diminished fitness, while N501Y exhibited comparable replication and fitness, highlighting the distinct effects of these spike protein mutations. The U76G mutation is located within a novel NSP9 binding site in the 5'-UTR and leads to impaired RNA synthesis and reduced viral replication efficiency, suggesting an important role in transcription and replication. Our findings highlight the robustness and adaptability of this reverse genetics system, providing a versatile, cost-effective tool for studying SARS-CoV-2 mutations and their effects on replication and fitness, with potential applications in vaccine and therapeutic development.

Indexed as

Reverse GeneticsSARS-CoV-25' Untranslated RegionsCost-Benefit AnalysisCOVID-19Genome, ViralHEK293 CellsHumansMutationPlasmidsRNA, ViralSpike Glycoprotein, CoronavirusVirus Replication5' Untranslated RegionsRNA, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2NSP9reverse genetic systemSARS-CoV-2spike

Identifiers

PMID41472274
PMCPMC12737603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.